Why is the CSL share price losing ground on Friday?

Why are CSL shares missing out on the market's gains on Friday?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's shaping up to be a rather pleasant end to the week for ASX shares and the S&P/ASX 200 Index (ASX: XJO). So far this Friday, the ASX 200 has put on a healthy 0.82% and is back over 7,150 points. But the same can't be said for the CSL Limited (ASX: CSL) share price.

CSL shares, at the time of writing, are in the red today. They've lost 0.47% of their value so far and are currently going for $268.75 each. So what's going on here? After all, this is an underperformance of the broader market of more than 1%.

A sad looking scientist sitting and upset about a share price fall.

Image source: Getty Images

Why is the CSL share price dropping today?

Well, it's not entirely clear. There hasn't been any news or announcements out of CSL today. Or indeed for a few weeks now.

But what we do know is that the S&P/ASX 200 Health Care Index (ASX: XHJ) is one of the worst-performing sectors on the ASX 200 today so far. Amongst ASX healthcare shares, Virtus Health Ltd (ASX: VRT) is leading the losses.

Virtus shares are presently down by a notable 1.1%. This could be related to the news we heard this morning, that Virtus has terminated the transaction implementation deed with European company CapVest in favour of a rival offer from BGH Capital.

The Virtus board is now unanimously recommending shareholders go with the BGH offer, even though the termination with CapVest will see Virtus pay a $7.19 million break fee.

This could be what is dragging the Virtus share price down today, and by extension, Virtus' woes could be why the entire healthcare sector, including the CSL share price, is under the pump.

At the current CSL share price, this ASX 200 healthcare giant has a market capitalisation of $129.42 billion, with a dividend yield of 0.96%.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Lab worker puts hands in the air and dances around.
Healthcare Shares

CSL shares look primed to take off — Here's why

Business remains robust and brokers see ASX stock soaring up to 100%.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

The ASX healthcare stock announced the outcome of its CEO recruitment drive this morning.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Could Telix shares be a millionaire-maker stock?

Telix looks a compelling growth story, with brokers eyeing more than 150% upside.

Read more »

A child covering his eyes hiding from a toy bear.
Healthcare Shares

Down 20% in 2026, is now the time to buy CSL shares?

CSL shares hit a new multi-year low as the 2026 decline deepens.

Read more »

Scientists in white coats look disappointed.
Healthcare Shares

Down 87% since Thursday, why is this ASX 300 healthcare stock sliding again today?

The ASX healthcare share has plunged more than 87% in five trading days.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which ASX biotech's shares have jumped more than 10% on positive clinical trial news?

A potential cancer treatment is progressing.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

3 ASX healthcare stocks tipped to soar over 100% higher this year

These ASX shares are on my radar this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »